Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
暂无分享，去创建一个
J. Baselga | J. Bendell | I. Braña | B. Haines | C. Winter | Theresa Zhang | S. Di Cosimo | S. Sathyanarayanan | R. Klinghoffer | A. Cervantes | S. Ebbinghaus | M. Stein | S. Jha | D. Roda | J. Frazier | Youyuan Xu | Yang Song | A. Leighton-Swayze | Jason P Frazier